Next Steps With Obesity-Related Genes in Patients With RCC

Julia R. Mendoza-Perez, PhD
Published: Monday, May 23, 2016

Julia R. Mendoza-Perez, PhD, visiting scientist, Epidemiology, The University of Texas MD Anderson Cancer Center, discusses next steps and research regarding obesity-related genes in patients with renal cell carcinoma (RCC).

In a study, researchers found that LEPR methylation is associated with kidney cancer tumorgenesis and that LEPR methylation levels were found to be significantly high in tumor tissue versus normal tissue. Additionally, these methylation levels are also associated with recurrence risk for kidney cancer as well as the clinical feature of the disease.

In the future, using this study’s tissue samples can help gain a deeper understanding of a tumor’s behavior and microenvironment, Mendoza-Perez explains. Additionally, she hopes that next steps will entail more research on molecular mechanisms, as there are several unanswered questions following the study’s findings.

In conclusion, Mendoza-Perez hopes to prevent disease recurrence with this research.
 
Julia R. Mendoza-Perez, PhD, visiting scientist, Epidemiology, The University of Texas MD Anderson Cancer Center, discusses next steps and research regarding obesity-related genes in patients with renal cell carcinoma (RCC).

In a study, researchers found that LEPR methylation is associated with kidney cancer tumorgenesis and that LEPR methylation levels were found to be significantly high in tumor tissue versus normal tissue. Additionally, these methylation levels are also associated with recurrence risk for kidney cancer as well as the clinical feature of the disease.

In the future, using this study’s tissue samples can help gain a deeper understanding of a tumor’s behavior and microenvironment, Mendoza-Perez explains. Additionally, she hopes that next steps will entail more research on molecular mechanisms, as there are several unanswered questions following the study’s findings.

In conclusion, Mendoza-Perez hopes to prevent disease recurrence with this research.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x